Hepatic function of FcRn revealed: Implications for overcoming drug‐mediated hepatotoxicity
E. Sally Ward, Raimund J. Ober – 17 August 2017
Projected increase in obesity and non‐alcoholic‐steatohepatitis–related liver transplantation waitlist additions in the United States
Neehar D. Parikh, Wesley J. Marrero, Jingyuan Wang, Justin Steuer, Elliot B. Tapper, Monica Konerman, Amit G. Singal, David W. Hutton, Eunshin Byon, Mariel S. Lavieri – 17 August 2017 – Nonalcoholic steatohepatitis (NASH) cirrhosis is the fastest growing indication for liver transplantation (LT) in the United States. We aimed to determine the temporal trend behind the rise in obesity and NASH‐related additions to the LT waitlist in the United States and make projections for future NASH burden on the LT waitlist.
Recurrent malignancy: Are we pushing the envelope?
Kwan Man – 17 August 2017
Fatty allograft and cardiovascular outcomes after liver transplantation
Rahima A. Bhanji, Kymberly D. Watt – 16 August 2017
Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000‐2014)
Reem Waziry, Jason Grebely, Janaki Amin, Maryam Alavi, Behzad Hajarizadeh, Jacob George, Gail V. Matthews, Matthew Law, Gregory J. Dore – 16 August 2017 – We assessed trends in HCC survival in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection in New South Wales, Australia. Data on HBV (n = 54,399) and HCV (n = 96,908) notifications (1993‐2012) were linked to a hospitalization database (July 2000‐June 2014), the New South Wales Cancer Registry, and the New South Wales Death Registry.
Advances in hypothermic perfusion
Pierre‐Alain Clavien, Philipp Dutkowski – 16 August 2017
Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
Yoshihiro Kamada, Masafumi Ono, Hideyuki Hyogo, Hideki Fujii, Yoshio Sumida, Makoto Yamada, Kojiroh Mori, Saiyu Tanaka, Tomohiro Maekawa, Yusuke Ebisutani, Akiko Yamamoto, Shinji Takamatsu, Masashi Yoneda, Norifumi Kawada, Kazuaki Chayama, Toshiji Saibara, Tetsuo Takehara, Eiji Miyoshi, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD) – 16 August 2017 – In contrast to patients with viral hepatitis, patients with nonalcoholic fatty liver disease (NAFLD) can progress to hepatocellular carcinoma during the initial stages of liver fibrosis.
Liver transplantation in adult cystic fibrosis: Clinical, imaging, and pathological evidence of obliterative portal venopathy
Sophie Hillaire, Dominique Cazals‐Hatem, Onorina Bruno, Sandra de Miranda, Dominique Grenet, Nicolas Poté, Olivier Soubrane, Serge Erlinger, Florence Lacaille, Francois Mellot, Valerie Vilgrain, Valerie Paradis – 16 August 2017
Society Leadership and Diversity: Hail to the Women!
Anna Lok, Carol A. Burke, Sheila E. Crowe, Karen L. Woods – 15 August 2017
Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention‐to‐treat analysis
Robbert J. de Haas, Chetana Lim, Prashant Bhangui, Chady Salloum, Philippe Compagnon, Cyrille Feray, Julien Calderaro, Alain Luciani, Daniel Azoulay – 14 August 2017 – The salvage liver transplantation (SLT) strategy was conceived for initially resectable and transplantable (R&T) hepatocellular carcinoma (HCC) patients, to try to obviate upfront liver transplantation, with the “safety net” of SLT in case of postresection recurrence. The SLT strategy is successful or curative when patients are recurrence free following primary resection alone, or after SLT for recurrence.